Neuropeptide Y autoantibodies in patients with long-term type 1 and type 2 diabetes and neuropathy.
Skärstrand, Hanna LU ; Dahlin, L B ; Lernmark, Åke LU
and Vaziri Sani, Fariba
LU
(2013)
In Journal of Diabetes and its Complications
27(6).
p.609-617
- Abstract
- Aims: The neurotransmitter Neuropeptide Y (NPY) was previously reported as a minor autoantigen in newly diagnosed type 1 diabetes (T1D) patients. The single nucleotide polymorphism at rs16139 (T1128C, L7P) in the NPY gene was associated with an increased risk for the development of type 2 diabetes (T2D). We aimed to develop a radiobinding assay for NPY-L (Leucine) and NPY-P (Proline) autoantibodies (A) to study the levels and the association with other islet autoantibodies and neuropathy. Methods: Autoantibodies against NPY-L, NPY-P, ZnT8, GAD65 and IA-2 were studied in T1D (n=48) and T2D (n=26) patients with duration up to 42 and 31years. A subgroup of T1D (n=32) patients re-examined, 5-8years after first visit, was tested for peripheral... (More)
- Aims: The neurotransmitter Neuropeptide Y (NPY) was previously reported as a minor autoantigen in newly diagnosed type 1 diabetes (T1D) patients. The single nucleotide polymorphism at rs16139 (T1128C, L7P) in the NPY gene was associated with an increased risk for the development of type 2 diabetes (T2D). We aimed to develop a radiobinding assay for NPY-L (Leucine) and NPY-P (Proline) autoantibodies (A) to study the levels and the association with other islet autoantibodies and neuropathy. Methods: Autoantibodies against NPY-L, NPY-P, ZnT8, GAD65 and IA-2 were studied in T1D (n=48) and T2D (n=26) patients with duration up to 42 and 31years. A subgroup of T1D (n=32) patients re-examined, 5-8years after first visit, was tested for peripheral (Z-score) and autonomic neuropathy (E/I ratio). Results: NPY-LA and NPY-PA were detected in 23% and 19% in T1D (p<0.001), and 12% and 23% in T2D patients (p<0.001) compared to 2.5% controls (n=398). The levels of NPYA declined during follow-up in the T1D patients (p<0.001). The neuropathy was not related to the NPYA or the other islet autoantibodies. Conclusions: Regardless of the absence of an association between NPYA and neuropathy, NPY may contribute to the pathogenesis of T1D and T2D as a minor autoantigen. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4006227
- author
- Skärstrand, Hanna
LU
; Dahlin, L B
; Lernmark, Åke
LU
and Vaziri Sani, Fariba
LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Diabetes and its Complications
- volume
- 27
- issue
- 6
- pages
- 609 - 617
- publisher
- Elsevier
- external identifiers
-
- wos:000327414600014
- pmid:23910631
- scopus:84887058054
- ISSN
- 1873-460X
- DOI
- 10.1016/j.jdiacomp.2013.06.007
- language
- English
- LU publication?
- yes
- id
- c35df53d-dfc3-4513-ac34-023aa4b61635 (old id 4006227)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23910631?dopt=Abstract
- date added to LUP
- 2016-04-01 10:11:01
- date last changed
- 2022-03-22 13:04:27
@article{c35df53d-dfc3-4513-ac34-023aa4b61635,
abstract = {{Aims: The neurotransmitter Neuropeptide Y (NPY) was previously reported as a minor autoantigen in newly diagnosed type 1 diabetes (T1D) patients. The single nucleotide polymorphism at rs16139 (T1128C, L7P) in the NPY gene was associated with an increased risk for the development of type 2 diabetes (T2D). We aimed to develop a radiobinding assay for NPY-L (Leucine) and NPY-P (Proline) autoantibodies (A) to study the levels and the association with other islet autoantibodies and neuropathy. Methods: Autoantibodies against NPY-L, NPY-P, ZnT8, GAD65 and IA-2 were studied in T1D (n=48) and T2D (n=26) patients with duration up to 42 and 31years. A subgroup of T1D (n=32) patients re-examined, 5-8years after first visit, was tested for peripheral (Z-score) and autonomic neuropathy (E/I ratio). Results: NPY-LA and NPY-PA were detected in 23% and 19% in T1D (p<0.001), and 12% and 23% in T2D patients (p<0.001) compared to 2.5% controls (n=398). The levels of NPYA declined during follow-up in the T1D patients (p<0.001). The neuropathy was not related to the NPYA or the other islet autoantibodies. Conclusions: Regardless of the absence of an association between NPYA and neuropathy, NPY may contribute to the pathogenesis of T1D and T2D as a minor autoantigen.}},
author = {{Skärstrand, Hanna and Dahlin, L B and Lernmark, Åke and Vaziri Sani, Fariba}},
issn = {{1873-460X}},
language = {{eng}},
number = {{6}},
pages = {{609--617}},
publisher = {{Elsevier}},
series = {{Journal of Diabetes and its Complications}},
title = {{Neuropeptide Y autoantibodies in patients with long-term type 1 and type 2 diabetes and neuropathy.}},
url = {{https://lup.lub.lu.se/search/files/1632880/4436185.pdf}},
doi = {{10.1016/j.jdiacomp.2013.06.007}},
volume = {{27}},
year = {{2013}},
}